SALL4 and acute myeloid leukemia: These results are similar to the findings of Jeong, HW et al. who showed that AML patients who responded to treatment had decreasing SALL4 expression throughout the course of treatment, while AML patients with disease relapse or drug resistance had increasing SALL4 expression, which was correlated with disease progression [15].